Breaking News Instant updates and real-time market news.

BIIB

Biogen

$318.11

-0.21 (-0.07%)

, MRK

Merck

$61.70

-0.6 (-0.96%)

06:53
11/23/16
11/23
06:53
11/23/16
06:53

Biogen drops 4%, Merck drops 1% following Lilly Alzheimer's failure

BIIB

Biogen

$318.11

-0.21 (-0.07%)

MRK

Merck

$61.70

-0.6 (-0.96%)

LLY

Eli Lilly

$75.99

-0.65 (-0.85%)

  • 29

    Nov

  • 03

    Dec

  • 04

    Dec

BIIB Biogen
$318.11

-0.21 (-0.07%)

11/07/16
MZHO
11/07/16
INITIATION
Target $290
MZHO
Neutral
Biogen initiated with a Neutral at Mizuho
Mizuho analyst Salim Syed initiated Biogen with a Neutral rating and a $290 price target.
11/09/16
RBCM
11/09/16
NO CHANGE
RBCM
Biotech stocks should be bought on post-election decline, says RBC Capital
RBC Capital recommends buying biotech stocks today on weakness. The firm notes that stocks usually rebound after they drop due to political events that don't affect their fundamentals, and it believes that the decline in biotech stocks today is in that category. The firm says that President-elect Trump probably won't focus on drug prices or Medicare reform. It adds that biotech companies should benefit from the fact that Congress will stay in GOP hands and the apparent failure of California's Proposition 61 initiative. The firm identifies Celgene (CELG), Biogen (BIIB), Vertex (VRTX), BioMarin (BMRN), and Prothena (PRTA) as its favorite names in the sector.
11/09/16
PIPR
11/09/16
NO CHANGE
PIPR
Piper sees improving environment for Biopharma M&A
The biotech sector is seeing a "massive relief rally" given the "surprise trifecta" of a Republican sweep, the voting down of Prop 61 in California and U.S. dollar weakness, Piper Jaffray analyst Joshua Schimmer tells investors in a research note. The door is now open to discuss potential repatriation of cash outside the U.S., which could be a green light on mergers and acquisitions, the analyst adds. He points out that Amgen (AMGN) and Gilead (GILD) hold the most overseas cash, with Celgene (CELG) and Biogen (BIIB) holding several billion as well. Schimmer believes the broader environment may be improving for M&A. He cautions, though, that the election of Trump does not remove the "major drug pricing overhang question."
11/08/16
11/08/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Adient (ADNT) initiated with a Neutral at JPMorgan. 2. JinkoSolar (JKS) initiated with a Buy at Craig-Hallum. 3. Amgen (AMGN), Gilead (GILD), and Celgene (CELG) initiated with a Buy at Mizuho while the firm initiated Biogen (BIIB) with a Neutral. 4. BioScrip (BIOS) resumed with a Buy at Jefferies. 5. SQM (SQM) initiated with a Market Perform at BMO Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
MRK Merck
$61.70

-0.6 (-0.96%)

10/13/16
10/13/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Merck (MRK) upgraded to Buy from Neutral at BofA/Merrill with analyst Colin Bristow citing its opportunity in first line lung cancer. 2. Viacom (VIA, VIAB) upgraded to Market Perform from Underperform at Wells Fargo and to Buy from Underperform at BofA/Merrill. 3. TD Ameritrade (AMTD) and Charles Schwab (SCHW) were upgraded to Buy from Neutral at BofA/Merrill. 4. Talend (TLND) upgraded to Buy from Neutral at Goldman with analyst Jesse Hulsing saying the company will benefit from analytic workloads moving to the cloud. 5. CSC (CSC) upgraded to Buy from Neutral at Citi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/19/16
LEER
10/19/16
NO CHANGE
LEER
Roche Tecentriq approval increases competition, says Leerink
Leerink analyst Seamus Fernandez says that the FDA approval of Roche's (RHHBY) Tecentriq in second-line non-small cell lung cancer patients regardless of PD-L1 expression comes as no surprise given its previously reported overall survival advantage. Nonetheless, the analyst believes it creates new competition for Bristol-Myers' (BMY) Opdivo and Merck's (MRK) Keytruda in this setting.
10/24/16
RHCO
10/24/16
NO CHANGE
RHCO
Merck Keytruda to have several positive catalysts, says SunTrust
SunTrust analyst John Boris says that several trials of Merck's Keytruda will be stopped early "across multiple tumor types," providing a positive catalyst. Boris says that Keytruda should be approved for 1LNSCLC on or before December 24 and KN-21 chemo combo compendium listing in 1H17. He keeps a $73 price target and Buy rating on Merck.
10/25/16
RHCO
10/25/16
NO CHANGE
RHCO
Merck shares should be bought after early FDA approval, says SunTrust
After Merck announced that the FDA had approved the company's Keytruda treatment for the first-line metastatic non-small cell lung cancer with tumor proportion scores of 50% or higher, SunTrust analyst John Boris says that such patients represent about 30% "of the prevalent first-line population." He adds that the approval was earlier than expected and gives Keytruda an approximately 15 month lead over competing drugs in NSCLC. The analyst thinks that the early approval will enable the company's 2021 revenue to beat expectations by a significant amount, and he recommends buying the stock on the news.
LLY Eli Lilly
$75.99

-0.65 (-0.85%)

11/11/16
JEFF
11/11/16
NO CHANGE
Target $100
JEFF
Buy
Jefferies bullish on Lilly regardless of Alzheimer's data
Jefferies analyst Jeffrey Holford believes shares of Eli Lilly "can work over time" regardless of Alzheimer's disease drug solanezumab's Phase III study outcome. The analyst, however, says he has enough confidence to recommend Lilly shares ahead of the EXPEDITION3 data readout. Holford increased his base case solanezumab peak sales to $5B. He says Lilly remains one of his top picks with a Buy rating and $100 price target.
11/09/16
SBSH
11/09/16
NO CHANGE
SBSH
Citi sees Healthcare 'relief rally' after Trump win
Citi analyst Andrew Baum expects a "'relief rally" to drive near-term sector outperformance for names in the Healthcare space given the "inability of the Democrats to attain the Presidency, the House or Congress." Longer term, however, the analyst still sees "significant continued legislative risk" for pharma reimbursement. Baum prefers GlaxoSmithKline (GSK), AstraZeneca (AZN), Shire (SHPG) and Roche (RHHBY) among European majors and Bristol-Myers (BMY) and Eli Lilly (LLY) in the U.S.
11/15/16
JPMS
11/15/16
NO CHANGE
Target $95
JPMS
Overweight
JPMorgan sees favorable risk/reward for Lilly into Alzheimer's data
JPMorgan analyst Chris Schott sees a favorable risk/reward profile for shares of Eli Lilly into the solanezumab data for Alzheimer's, which is expected by year-end. Favorable data from the EXPEDITION-3 trial would represent a catalyst not just for Lilly and other Alzheimer's associated names but for the biopharma space as a whole, Schott tells investors in a research note. The analyst expects 20%-plus share upside in the event the trial is successful on both primary and secondary endpoints. He assigns a 10%-20% probability to this outcome. Schott sees 10%-20% share upside for Lilly should the study hit on its primary but only shows a trend on secondary endpoints. He assigns a 50%-60% probability for this outcome. The analyst also sees a 10% move to the downside if the study fails both endpoints, an outcome he assigns a 20% probability. Schott reiterates an Overweight rating on Lilly with a $95 price target. He believes Lilly's "diverse range of pipeline opportunities" largely supports the valuation at current levels.
11/03/16
BMOC
11/03/16
NO CHANGE
BMOC
Eli Lilly factored pricing pressure into guidance, says BMO Capital
After meeting with Eli Lilly, BMO Capital analyst Alex Arfaei reports that the company seemed surprised at the intensity of investors' concerns about pricing pressure on it. The analyst says that the company anticipated pricing pressure and factored it into its guidance. The analyst keeps a $91 price target and an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

BRSS

Global Brass and Copper

$33.30

-0.55 (-1.62%)

18:47
01/22/18
01/22
18:47
01/22/18
18:47
Hot Stocks
Global Brass and Copper reports oil spill at Somers Thin Strip plant »

Somers Thin Strip, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$227.58

7.12 (3.23%)

, DIS

Disney

$111.10

0.51 (0.46%)

18:38
01/22/18
01/22
18:38
01/22/18
18:38
Hot Stocks
Netflix doesn't see Disney-Fox deal as a direct threat »

Says Disney (DIS) and Fox…

NFLX

Netflix

$227.58

7.12 (3.23%)

DIS

Disney

$111.10

0.51 (0.46%)

FOX

21st Century Fox

$36.96

0.7 (1.93%)

FOXA

21st Century Fox

$37.31

0.66 (1.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 30

    Jan

  • 06

    Feb

  • 07

    Feb

  • 07

    Feb

T

AT&T

$37.87

0.66 (1.77%)

, TWX

Time Warner

$94.00

0.64 (0.69%)

18:37
01/22/18
01/22
18:37
01/22/18
18:37
Periodicals
Judge orders DOJ to seek consent to give data to AT&T, Time Warner, Reuters says »

Judge Richard Leon, who…

T

AT&T

$37.87

0.66 (1.77%)

TWX

Time Warner

$94.00

0.64 (0.69%)

DIS

Disney

$111.10

0.51 (0.46%)

FOX

21st Century Fox

$36.96

0.7 (1.93%)

FOXA

21st Century Fox

$37.31

0.66 (1.80%)

VIA

Viacom

$39.30

0.1 (0.26%)

VIAB

Viacom

$33.94

0.58 (1.74%)

DISCA

Discovery

$26.33

0.62 (2.41%)

SNI

Scripps Networks

$88.77

0.27 (0.31%)

CMCSA

Comcast

$42.89

0.39 (0.92%)

CMCSK

Comcast

CHTR

Charter

$370.25

4.2 (1.15%)

ATUS

Altice USA

$21.90

0.6 (2.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 31

    Jan

  • 02

    Feb

  • 06

    Feb

  • 07

    Feb

  • 07

    Feb

  • 08

    Feb

  • 08

    Feb

  • 12

    Feb

  • 27

    Feb

NFLX

Netflix

$227.58

7.12 (3.23%)

18:25
01/22/18
01/22
18:25
01/22/18
18:25
Hot Stocks
Netflix says it has a ways to go to hit 60M U.S. subscribers »

Says has a ways to go to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 30

    Jan

BIVV

Bioverativ

$103.79

39.68 (61.89%)

, SNY

Sanofi

$43.20

-1.4 (-3.14%)

18:15
01/22/18
01/22
18:15
01/22/18
18:15
Downgrade
Bioverativ, Sanofi rating change  »

Bioverativ downgraded to…

BIVV

Bioverativ

$103.79

39.68 (61.89%)

SNY

Sanofi

$43.20

-1.4 (-3.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 14

    Feb

  • 16

    Feb

  • 08

    Mar

  • 25

    Mar

  • 25

    Apr

  • 02

    May

ECR

Eclipse Resources

$2.33

0.05 (2.19%)

18:12
01/22/18
01/22
18:12
01/22/18
18:12
Conference/Events
Eclipse Resources to host analyst day »

Analyst Day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$227.58

7.12 (3.23%)

18:10
01/22/18
01/22
18:10
01/22/18
18:10
Hot Stocks
Netflix says Asia market projects 'well' »

Says very pleased with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 30

    Jan

STLD

Steel Dynamics

$46.57

0.15 (0.32%)

18:06
01/22/18
01/22
18:06
01/22/18
18:06
Hot Stocks
Steel Dynamics CEO says domestic inventory levels moderated »

Steel Dynamics CEO Mark…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

STLD

Steel Dynamics

$46.57

0.15 (0.32%)

18:04
01/22/18
01/22
18:04
01/22/18
18:04
Earnings
Steel Dynamics reports Q4 EPS 54c excluding items, consensus 52c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

IMI

Intermolecular

$1.61

0.14 (9.52%)

18:02
01/22/18
01/22
18:02
01/22/18
18:02
Hot Stocks
Intermolecular and SITRI expand alliance to address Chinese market »

Intermolecular and SITRI…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

EXFO

EXFO Inc.

$4.35

-0.05 (-1.14%)

, CHL

China Mobile

$51.97

0.45 (0.87%)

18:01
01/22/18
01/22
18:01
01/22/18
18:01
Hot Stocks
EXFO partners with China Mobile to prepare network for IoT »

EXFO Inc. (EXFO)…

EXFO

EXFO Inc.

$4.35

-0.05 (-1.14%)

CHL

China Mobile

$51.97

0.45 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$111.12

-1.84 (-1.63%)

18:00
01/22/18
01/22
18:00
01/22/18
18:00
Hot Stocks
Celanese announces acetyl intermediates price increases »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jan

SFNC

Simmons First National

$59.50

0.35 (0.59%)

18:00
01/22/18
01/22
18:00
01/22/18
18:00
Earnings
Simmons First National reports Q4 core EPS 97c, consensus 88c »

Reports Q4 core net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

WHR

Whirlpool

$166.65

-0.88 (-0.53%)

, SSNLF

Samsung

17:59
01/22/18
01/22
17:59
01/22/18
17:59
Hot Stocks
Whirlpool chairman praises Trump's move to establish tariff on washing machines »

Whirlpool (WHR) chairman…

WHR

Whirlpool

$166.65

-0.88 (-0.53%)

SSNLF

Samsung

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 30

    Jan

AMBC

Ambac Financial

$16.02

0.07 (0.44%)

17:48
01/22/18
01/22
17:48
01/22/18
17:48
Hot Stocks
Ambac Financial announces approval of plan amendment »

Ambac Financial Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STML

Stemline

$14.25

0.7 (5.17%)

17:47
01/22/18
01/22
17:47
01/22/18
17:47
Conference/Events
Stemline participates in a conference call with JPMorgan »

Investor conference call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

EFSC

Enterprise Financial

$47.70

-0.025 (-0.05%)

17:42
01/22/18
01/22
17:42
01/22/18
17:42
Earnings
Enterprise Financial reports Q4 EPS 77c, consensus 77c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

RARE

Ultragenyx

$53.39

4.23 (8.60%)

17:41
01/22/18
01/22
17:41
01/22/18
17:41
Conference/Events
Ultragenyx participates in a conference call with JPMorgan »

Investor conference call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Apr

  • 24

    Jan

FDEF

First Defiance Financial

$53.79

-0.77 (-1.41%)

17:34
01/22/18
01/22
17:34
01/22/18
17:34
Earnings
First Defiance Financial reports Q4 adjusted EPS 92c, consensus 89c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

SJR

Shaw Communications

$21.78

0.19 (0.88%)

17:29
01/22/18
01/22
17:29
01/22/18
17:29
Syndicate
Breaking Syndicate news story on Shaw Communications »

Shaw Communications files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPIX

ESSA Pharma

$0.22

-0.0141 (-6.02%)

17:29
01/22/18
01/22
17:29
01/22/18
17:29
Syndicate
Breaking Syndicate news story on ESSA Pharma »

ESSA Pharma files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

WRLD

World Acceptance

$87.87

2.42 (2.83%)

17:22
01/22/18
01/22
17:22
01/22/18
17:22
Hot Stocks
CFPB completes investigation in World Acceptance, will not recommend action »

World Acceptance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jan

17:20
01/22/18
01/22
17:20
01/22/18
17:20
Conference/Events
CFA Society of New York to hold a discussion »

The CFA Society of New…

RBB

RBB Bancorp

$26.97

0.09 (0.33%)

17:19
01/22/18
01/22
17:19
01/22/18
17:19
Earnings
RBB Bancorp reports Q4 EPS with items 29c, consensus 39c »

Reports Q4 provision for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

WRLD

World Acceptance

$87.87

2.42 (2.83%)

17:18
01/22/18
01/22
17:18
01/22/18
17:18
Hot Stocks
World Acceptance names Jim Wanserski interim president, CEO »

World Acceptance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.